Founded in 2021, Odyssey Therapeutics is a Boston-based biotechnology company focused on discovering, developing, and commercializing the next generation of immunomodulators and oncology medicines. Odyssey is building an industry leading discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Led by CEO Dr. Gary Glick, Odyssey raised a $100m Series C round in October, 2023, led by Ascenta.